LVTX Projected Dividend Yield
Ord/LAVA Therapeutics NV ( NASDAQ : LVTX )Lava Therapeutics is a biotechnology company. Through its subsidiary, Co. is engaged in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Co.'s product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Co. also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. 21 YEAR PERFORMANCE RESULTS |
LVTX Dividend History Detail LVTX Dividend News LVTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |